Cargando…
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy
To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin targeted agent vinflunine (VFL) (320 mg m(−2) q 21 days) as second-line chemotherapy in patients with metastatic breast carcinoma (MBC). All patients had disease progression after anthracycline/taxane (A/T)...
Autores principales: | Campone, M, Cortes-Funes, H, Vorobiof, D, Martin, M, Slabber, C F, Ciruelos, E, Bourbouloux, E, Mendiola, C, Delgado, F M, Colin, C, Aslanis, V, Fumoleau, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360552/ https://www.ncbi.nlm.nih.gov/pubmed/17031408 http://dx.doi.org/10.1038/sj.bjc.6603347 |
Ejemplares similares
-
Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016) -
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
por: Culine, S, et al.
Publicado: (2006) -
Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009) -
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009) -
Vinflunine in the treatment of bladder cancer
por: Bachner, Mark, et al.
Publicado: (2008)